Non-Small Cell Lung Cancer
Razor Genomics Inc. is active in non-small cell lung cancer research, with a specific focus on patients who have undergone complete surgical resection and have early-stage disease. Its clinical activity centers on the non-squamous subtype of NSCLC, reflecting interest in postoperative disease management and risk assessment.
- Completely resected stage I or IIA NSCLC
- Non-squamous lung cancer
- Postoperative lung cancer care
The sponsor’s research landscape includes collaboration across multiple sites in the United States and other active trial regions, supporting clinical evaluation in early-stage thoracic oncology.
Molecular Prognostic Testing
The sponsor’s work is closely tied to molecular prognostic testing in lung cancer, particularly the use of a 14-gene prognostic assay to identify patients at higher or intermediate risk after surgery. This places emphasis on biomarker-informed stratification in clinical oncology.
- 14-gene prognostic assay
- Risk stratification in resected disease
- Biomarker-guided patient selection
Its research activity reflects interest in linking genomic information with treatment decisions for patients with early-stage NSCLC.
Adjuvant Chemotherapy
Razor Genomics Inc. also has a therapeutic focus on adjuvant chemotherapy for patients with resected early-stage lung cancer. The clinical question being explored is whether postoperative systemic therapy can improve outcomes in those identified as having elevated recurrence risk.
- Platinum-based doublet therapy
- Adjuvant treatment after surgery
- Disease-free survival in early-stage lung cancer
This area of interest connects genomic risk assessment with postoperative treatment planning in thoracic oncology.
Personalized Oncology
The sponsor’s clinical research is centered on personalized oncology, using molecular findings to guide decisions about whether patients should be observed or receive additional therapy after resection. This aligns its work with precision medicine approaches in cancer care.
- Precision medicine in lung cancer
- Post-surgical treatment decision-making
- Individualized recurrence-risk assessment
Its clinical interest lies in refining management pathways for patients with early-stage NSCLC based on molecular risk features.
